(1) Inhibit plasminogen activators, preventing plasminogen from activating into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect. (2) Promote the release of active substances from platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect. (3) Enhance capillary resistance and reduce capillary permeability, thereby reducing bleeding.

Lomeza is a broad-spectrum quinolone antibiotic that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

This product is a sulfonamide antibiotic that interferes with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double-block the bacterial folic acid metabolism, especially against Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus. The antibacterial effect is significantly enhanced compared with a single drug.

It selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folate metabolism. The synergistic antibacterial effect is stronger than that of a single drug, and the number of drug-resistant strains is reduced.